According to a new market report from Transparency Market Research, a global market intelligence company, the global antibacterial drugs market was valued at $43.55 billion in 2012 and is expected to grow at a CAGR of 0.3% from 2013 to 2019, to reach an estimated value of $45.09 billion in 2019.
Antibacterial drugs have been utilized by humans since the discovery of the first antibiotic penicillin in 1928 and have grown into a multi-billion dollar market. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria, which cannot be treated by any other method unlike other diseases, where substitute methodologies are available. According to the study Antibacterial Drugs—Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019, this property has made antibacterial drugs an indispensable part of human healthcare.
Antibacterial drugs are classified into seven major classes: aminoglycosides, beta-Lactams, tetracyclines, sulfonamides, quinolones, macrolides and phenicols. The beta-lactams class was the largest segment of the global antibacterial drugs market in 2012, with 57% share. Quinolones was identified as the second largest class, which held a share of 16.6% of the global antibacterial drugs market in 2012 and is expected to report a negative CAGR during the forecast period. This decline in revenue primarily will be due to sales erosion from patent expiries, evolution of resistant strains of bacteria and rising concerns regarding tendon ruptures and tendon damage from fluoroquinolones therapy. However, the demand for macrolides and quinolones/fluoroquinolones classes will remain high during the forecast period, due to their usage in treating a large number of infections coupled with expected launch of pipeline drugs in these classes during the forecast period.
Factors such as increasing prevalence of infectious diseases and rising demand for effective as well as affordable antibacterial drugs especially from emerging economies of Asia-Pacific, Latin America, Middle East and Africa are the major growth drivers for the antibacterial drugs market.
Globally, the rise in elderly population also is being considered as one of the major growth factors as it will indirectly increase the demand for various antibacterial drugs. The demand for antibacterial drugs will continue to rise regardless of presence of a wide range of antibacterial drugs. This is mainly due to increased prevalence of resistant species that demand development of innovative molecules.
In 2012, Asia-Pacific held the largest share of the revenue generated by the global antibacterial drugs market. This region also is set to experience the highest growth rate during the forecast period 2013 to 2019, because it accounts for the largest infected population in the world, by a variety of bacterial infections such as pneumonia, tuberculosis and tetanus. Other factors include increasing multi-drug resistant bacterial strains, increasing availability of generic drugs and increasing purchasing power of the people of this region. India, one of the key markets in the Asia-Pacific region, is the largest generic drug manufacturing nation. North America held the second largest revenue share, followed by Europe in the antibacterial drugs market in 2012.
At present, certain novel compounds are under investigation in both preclinical and clinical settings for the treatment of newly evolving drug-resistant bacterial species. Some of the major candidates such as Dalvance (Durata Therapeutics), tedizolidand surotomycin (Cubist Pharmaceuticals) and others currently are in phase III clinical trials. These drugs promise to provide improved efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Hence, expected launch of these drugs during the forecast period is anticipated to have a profound impact on the growth of the overall antibacterial drugs market.
With very few patented products currently available in this market, the market is dominated by generic manufacturers. With respect to the key revenue generating drugs (branded and generic) of this market, Pfizer accounted for the largest market share in 2012, followed by Merck and GlaxoSmithKline.